The efficacy and safety of hachimijiogan for mild Alzheimer's disease

The efficacy and safety of hachimijiogan for mild Alzheimer's disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071190018

Enrollment

Registered

2019-08-02

Start date

2019-08-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild Alzheimers disease Hachimijiogan, mild Alzheimers disease

Interventions

One group will take hachimijiogan powder 7.5g/day for 6 months along with their previous standard treatment.The other group will continue the previous standard treatment for 6 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age:>=50 to =21) 3) Using the same dose of Donepezil, Galantamine, or Rivastigmine for more than three months 4) Not taking Memantine 5) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Taking Kampo Medicine other than Hachimijiogam 2) Kidney disfunction (eGFR100 IU/L 4) Change of drug dosage that could affect the progression cognitive function during the three months 5) Complication with gastric ulcer, bronchial asthma, or epilepsy. 6) Judged by doctors not to be suited for study, such as having serious complications.

Design outcomes

Primary

Measure	Time frame
ADAS-Jcog	—

Secondary

Measure	Time frame
IADL(Instrumental Activity of Daily Life) Apathy scale NPI(Nueropsychiatric Inventor)	—

Contacts

Public ContactMosaburo Kainuma

Toyama University Hospital

kainuma@med.u-toyama.ac.jp+81-76-434-7393

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026